AbbVie Inc. is a prominent biopharmaceutical company with a global footprint, known for its innovations in immunology, oncology, neuroscience, and aesthetics. Headquartered in North Chicago, AbbVie was formed in 2013 after its spin-off from Abbott Laboratories.

Currently, AbbVie’s stock is trading at around $212 per share. Analysts are closely watching its growth trajectory, especially with newer products like Skyrizi and Rinvoq. Many forecasts suggest that AbbVie’s stock could reach $300 within the next 12 to 18 months, driven by continued growth in its immunology segment and pipeline developments.

From an investment perspective, AbbVie offers a solid dividend yield (above 3%) and a diversified revenue base, which makes it attractive for long-term investors. However, as with all biotech stocks, there are inherent risks, including regulatory hurdles and competitive pressures. Thus, while many analysts consider it profitable in the long run, it requires a careful, risk-aware approach.

As for future trading, AbbVie is generally considered a stable stock, but it may not be the easiest for short-term trading due to moderate volatility. Long-term investors may find it a more secure bet, while short-term traders should be cautious and keep an eye on quarterly earnings reports and pipeline progress.